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Background: To retrospectively access outcome and toxicity of whole brain radiotherapy (WBRT) in patients with
multiple brain metastases (BM) from malignant melanoma (MM).
Patients and methods: Results of 87 patients (median age 58 years; 35 female, 52 male) treated by WBRT for BM
of MM between 2000 and 2011 were reviewed. Total dose applied was either 30 Gy in 10 fractions (n = 56) or 40 Gy
in 20 fractions (n = 31). All but 9 patients suffered from extra-cerebral metastases. Prior surgical resection of BM was
performed in 18 patients, salvage stereotactic radiosurgery in 13 patients.
Results: Mean follow-up was 8 months (range, 0–57 months), the 6- and 12-months overall-(OS) survival rates were
29.2% and 16.5%, respectively. The median OS was 3.5 months. In cerebral follow-up imaging 6 (11) patients
showed a complete (partial) remission, while 11 (17) patients had stable disease (intra-cerebral tumor progression).
In comparison of total dose, the group treated with 40 Gy in 20 fractions achieved a significant longer OS
(p = 0.003, median 3.1 vs. 5.6 months). Furthermore, DS-GPA score (p < 0.001) as well as RPA class (p < 0.001)
influenced significantly on OS and patients had a significantly longer OS after surgical resection (p = 0.001, median
3.0 vs. 5.8 months, multivariate p = 0.007). Having extra-cerebral metastases didn't significantly impact on OS
(p = 0.21).
Conclusion: Treatment of BM from MM with WBRT is tolerated well and some remissions of BM could be achieved.
An advantage for higher treatment total doses was seen. However, outcome is non-satisfying, and further
improvements in treatment of BM from MM are warranted.
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The malignant melanoma accounts for approximately
4.3% of all cancers in Germany in females and 3.2% in
males, respectively and causes around 1% of all cancer
deaths. In the last 30 years, the age standardized inci-
dence rates in Germany tripled [1]. Furthermore, the risk
of development of brain metastases is stage dependent
and as high as 46% in stage IV [2-6]. The median survival
is short and reported to be about 4–5 months [7,8]. In
case of brain metastases surgical resection should be* Correspondence: henrik.hauswald@med.uni-heidelberg.de
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reproduction in any medium, provided the orevaluated, even though brain metastases might be too
small for resection or simply too frequent [9]. The stand-
ard of care in brain metastases from malignant melanoma
includes WBRT delivered as 30 Gy in 10 fractions, or
40 Gy in 20 fractions [10-17]. This results in a median
survival of 3–5 months [7,10-17]. Due to the limited effi-
cacy of WBRT, and due to the advent of high precision
radiosurgery techniques, radiosurgery (SRS) has been
established for subgroups of patients with 1–3 brain me-
tastases. It has been shown that in these patients WBRT
plus surgery or SRS leads to an increase of loco-regional
control compared to local treatments alone, however,
overall survival is unaltered [18]. However, in this ana-
lysis, several tumor types with high numbers of breastral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics









n. a. 38 44
Distant metastases
Extra-cerebral 75 86
Only cerebral 9 10
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reported high efficacy of SRS for patients with malignant
melanoma brain metastases: Seung et al. treated 140
lesions in 46 patients, with progression-free rates of 86%
at 6 and 76% at 12 months, respectively [19,20]. Grob
and co-workers published a local control rate of 98% at
3 months for 56 metastases in 35 patients treated with
SRS only, without additional WBRT. Median survival
was longer in patients with single lesions, i.e. 7.5 months
versus 4 months [21]. Our own data published previ-
ously was based on 64 patients treated for 122 lesions;
in this group, local control was 81% at 12 months, and
median survival after treatment was 10.6 months [22].
Another approach would be stereotactic brachytherapy
using 125-iodine seeds in solitary brain metastases, giv-
ing the advantage of histological evaluation [23]. Pub-
lished prognostic factors include RTOG-RPA class as
well as Karnofsky Performance score (KPI), Disease-
Specific Graded Prognostic Assessment Score (DS-GPA-
score), number of brain metastases and pretreatment
lactase-dehydrogenate level [11,24-27]. However, in
some cases, SRS is not possible, or multiple metastases
(>3) are present, and WBRT is indicated. In the present
work we focused on patients with cerebral metastases




Between 2000 and 2011 in total 87 patients (median age
58 years; 35 female, 52 male) with multiple brain metas-
tases from malignant melanoma were treated at the De-
partment of Radiation Oncology at the University
Hospital of Heidelberg. Prior surgical resection of brain
metastases was performed in 18 patients and salvage
SRS in 13 patients during the course of their disease.
Nine patients had metastases to the brain only, all other
additionally multiple extra-cerebral metastases. A sum-
mary is found in Table 1.
Radiotherapy and follow-up
Radiotherapy was performed as a WBRT delivered in
total doses of either 30 Gy in 10 fractions (n = 56; 3 Gy /
fraction, 5 fractions a week) or 40 Gy in 20 fractions
(n = 31; 2 Gy / fraction, 5 fractions a week) and adminis-
tered by opposing lateral 6-MeV photon beams. An add-
itional boost irradiation was performed in 8 patients
(SRS n = 2, 3D-CRT n= 6). All patients were followed
primarily by clinical examinations (n = 41), or by add-
itional imaging procedures as CT or MRI (n = 46). Of
these 46 patients with follow-up imaging procedure 24%
(n = 11) had surgery prior to WBRT and 11% (n = 5) a
boost irradiation. Furthermore, salvage SRS was carried
out in 24% of these patients (n = 11).Evaluation and statistics
Statistical analyses were carried out with SPSS statistical
package (SPSS Inc., Chicago, IL, U.S.A.) using log-rank
test (Mantel-Cox), Kaplan-Meier’s estimation for overall
survival (OS), Chi-square test (Pearson and Fisher exact
test) and multivariate Cox-regression analysis (back-
wards stepwise, p out >0.1, factors included: total dose
of irradiation (30 vs. 40 Gy), prior surgical resection, age
(>/= or <58 years), GPA-score and extra-cerebral metas-
tases). Significance was defined as p-value <0.05. All
time estimates began with the initiation of radiation
treatment. Observation of response and toxicity was per-




The mean follow-up time was 8 months (range, 0–
57 months). Cerebral follow-up imaging was performed
in 46 patients. Six patients achieved a complete remis-
sion (CR) and 11 patients a partial remission (PR), while
11 patients showed an intracerebral stable disease (SD),
1 patient a mixed response (MR) and 17 patients an
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a significantly improved OS (p < 0.001) with median
13.5 months compared to 4.4 months in patients with-
out remission and 2.4 months in patients without infor-
mation on imaging outcome. Furthermore, the majority
of patients were additionally treated with steroids for
clinically symptomatic brain edema or significant brain
edema seen in cerebral imaging procedures. Thirty-two
patients reported improved symptoms. Twenty-four
patients reported to be asymptomatic at end of treat-
ment, 19 patients to have stable symptoms and 8
patients described worsening of symptoms.
Survival
The median overall survival time was 3.5 months (range,
0.5-58 months) and the 6-, 12- and 24-months overall
survival rates were 29.2%, 16.5% und 8.6%, respectively
(Figure 1). At last follow-up, 9 patients were alive, while
78 had passed. The cause of death was documented as
progressive disease in 11 patients (14.1%), intracerebral
hemorrhage in 3 patients (3.8%), pulmonary embolism
in 2 patients (2.6%), meningeosis melanomatosa in 2
patients (2.6%), respiratory failure in 2 patients (2.6%)
and liver failure in 1 patient (1.3%). In 57 patients (73%)
the cause of death was not documented. In univariate
analysis, no significant influence on OS was seen for age
(p = 0.314), gender (p = 0.729), Clark level (CL, p = 0.786,
median CL III, analyzed CL >/= or < III), tumor thick-
ness (TT, p = 0.646, 2.25 mm, analyzed TT >/=
or < 2.25 mm) and having extra-cerebral metastases
(p = 0.206, median 5.1 months without versus 3.2 months
with). A significant influence on survival was seen inFigure 1 Kaplan-Meier estimation of overall survival (n=87).patients having had a surgical resection of at least one
cerebral metastasis, while in 2 of these patients a single
brain metastasis was resected (p = 0.001, median 5.8 ver-
sus 3.0 months, Figure 2). Chi-square analysis showed
that patients with higher DS-GPA scores were more
likely to have surgical resection of BM (Pearson,
p = 0.022). On the other hand, patients were not signifi-
cantly different distributed between the two different
dose concepts regarding surgical resection prior to ir-
radiation (Fisher exact test, p = 0.084) and salvage SRS
(Fisher exact test, p = 0.286). Patients in RPA class I had
a median OS of 44 months, in class II of 4.1 months and
in class III of 1.3 months (p < 0.001, Figure 3). Further-
more, DS-GPA-score was prognostic (median OS in
patients with 0 points 1.3 months, 1 point 3.9 months
and 2 points 7.2 months, p < 0.001, Figure 4). A higher
total treatment dose resulted in better outcome
(p = 0.003, median 5.6 months vs. 3.1 months, Figure 5).
Chi-square test showed that patients with DS-GPA
scores 0–3 were not statistically significantly distributed
between treatment groups with total doses of 30 Gy or
40 Gy (Pearson, p > 0.05). In multivariate analysis, total
treatment dose (p = 0.042), surgical resection (p = 0.007)
and GPA-score (p = 0.04) were prognostic. The results of
the uni- and multivariate analyses were summarized in
Table 2 and 3.
Side effects
Acute side effects at the end of the irradiation were
available in 84 patients (97%). At the end of radiation
treatment, 68 patients denied acute side effects, while 10
patients reported up to moderate (grade II-III) fatigue,
Figure 4 Kaplan-Meier estimation of overall survival according
to the DS-GPA score (score 0, n=12; score 1, n=40; score 3,
n=18).
Figure 2 Kaplan-Meier estimation of overall survival in patients
with (n=18) and without (n=66) prior resection of at least one
brain metastasis.
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IV) nausea, deficits in concentration and walking, brain
edema, solitary headache as well as headache and dizzi-
ness. Long-term side effects were reported by two
patients as fatigue and forgetfulness, respectively. The
development of acute side effects did not significantly
influence OS (p = 0.596).Figure 3 Kaplan-Meier estimation of overall survival according
to the RPA classes (class 1, n=4; class 2, n=55; class 3, n=13).Discussion
This retrospective analysis reports on the treatment
results of 87 patients treated between 2000 and 2011 for
multiple cerebral metastases in malignant melanoma.
The treatment consisted of a WBRT with a total treat-
ment dose of either 30 Gy or 40 Gy. This analysisFigure 5 Kaplan-Meier estimation of overall survival in patients
treated with 40 Gy in 20 fractions (n=31) versus 30 Gy in 10
fractions (n=56).
Table 2 Results of the univariate analyses (Log-rank,
Mantel-Cox)
Factor analyzed p-value
Development of side effects 0.596
Gender 0.729
Age (>/= vs. <58 years) 0.314
Clark level (>/= vs. < CL III) 0.786




Surgical resection of BM 0.01
Total treatment dose (30 vs. 40 Gy) 0.003
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prognostic factors to help finding ways to improve prog-
nosis, morbidity and mortality in patients with multiple
brain metastases in malignant melanoma.
The short median overall survival with 3.5 months is
consistent with reports by Rate et al. and Stevens et al.,
who published a median survival after the development
of brain metastases between 14 weeks and 5 months
[14,16]. In the cohort of Rate et al., a factor associated
with improved survival was surgical resection of a soli-
tary brain metastasis, which led to a median survival of
36 weeks. The Analysis of Stevens et al. revealed
complete macroscopic resection of all cerebral disease,
absence of extra cerebral metastases and a single brain
metastasis to be associated with improved survival.
Long-term survival of > 2 years in 10 patients was asso-
ciated with solitary brain metastasis and surgical resec-
tion. Comparable results were reported by Fife et al. [7].
In 2010 Eigentler et al. concluded that number of brain
metastases (solitary versus multiple) and pre-treatment
lactase-dehydrogenate (LDH) levels were primarily
impacting on overall survival [26]. Unfortunately the
pre-treatment LDH levels in our cohort were retrospect-
ively not accessible, and additionally all patients except
for two had multiple intracerebral metastases, since
patients with one to three brain metastases from malig-
nant melanoma are treated with SRS in our department.
So our cohort represents patients with at least oneTable 3 Results of the multivariate analysis
(Cox-regression)
Factor analyzed p-value
Surgical resection of BM 0.007
DS-GPA score 0.04
Total treatment dose (30 vs. 40 Gy) 0.042
Age 0.7
Extra-cerebral metastases 0.52negative prognostic factor: multiple brain metastases
from malignant melanoma. One other factor influencing
survival was RPA classification, which especially showed
reduced survival in patients with RPA class III, while
class I had the best prognosis, but one should keep the
retrospective character of this analysis in mind. In the
publication by Broadbent et al. on 474 patients with brain
metastases −198 patients with brain metastases due to
MM- survival in RPA classes I-III were 7.7 months,
4.7 months and 2.1 months, respectively [10]. This com-
pared well with data reported by Gaspar et al., were sur-
vival in RPA classes I-III were 7.1 months, 4.2 months
and 2.3 months, respectively [25]. Comparable results
were seen regarding the DS-GPA score. As previously
described by Sperduto et al. [27], patients with higher
DS-GPA scores had significantly improved survival in
our cohort. Furthermore, our data showed an increased
survival for treatment with higher total doses; likely
caused by the relative radioresistant biology. In the lit-
erature, Broadbent et al. reported a dose response with
a median survival of 4.7 months for 30 Gy in 10 frac-
tions and 3.0 months for 20 Gy in 5 fractions[10]. Fur-
ther on, 42 patients were treated with doses above 30 Gy,
which seemed to further improve survival (median
12.9 months). The hypothesis that patients with brain
metastases from malignant melanoma might benefit
from a dose escalation beyond 30 Gy was posed by Rades
et al. [28]. In relative radioresistant tumors an increase in
total dose might improve tumor control and thereby
long-term outcome. Radiosurgery (RS) has shown to be
able to achieve 1-year local tumor controls as high as
81% in brain metastases from malignant melanoma. The
combination of RS and WBRT might reduce local fail-
ures as reported by Brown et al. or Rades and Schild
even though other reports (e.g. Liew et al.) did not
show improved local control by adding WBRT to RS
[29-32]. Or after resection of a solitary brain metasta-
ses, WBRT + boost to the metastastic region increases
local control, but not survival [33]. Still, the next step
might be to perform a primary WBRT with integrated
boost to the brain metastases. A phase one trial of sim-
ultaneous in-field boost with helical tomotherapy for 1 to
3 brain metastases did not show dose-limiting central
nervous system toxicity [34]. So this approach might play
a role in treatment of brain metastases from malignant
melanoma in the future. Additionally the combination of
WBRT and systemic treatment such as Ipilimumab might
be a potential treatment approach in malignant melan-
oma and will be evaluated in a prospective randomized
trial (ELEKTRA).
Conclusion
The treatment of multiple brain metastases from malig-
nant melanoma with WBRT is well tolerated and
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eral cases. A dose response with an advantage for higher
total treatment doses was seen. However, treatment out-
come is non-satisfying, and further improvements in
treatment of brain metastases from malignant melanoma
are warranted.
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